Pozen rated outperform by RBC

RBC Capital Markets analyst Ken Trbovich rated Pozen, Inc. at outperform, speculative risk. And $15 price target. According to the analyst, the AstraZeneca partnership is worth at least $5 to $6 per share. Pozen traded up 40%, or almost $3.00, on announcement of the deal. Peak sales could reach $1 billion in 2013, considering that COX-2 inhibitors achieved $2 billion to $3 billion in sales after four or five years on the market. Shares of the Chapel Hill, N.C.-based development stage company were up 1 cent, or 0.10%, at $10.45, on volume of 2,420,676 shares versus the three-month running average of 1,690,940 shares. (Nasdaq: POZN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.